- Dec 31 Sat 2011 18:03
- Dec 30 Fri 2011 04:12
Dutch scientists enrolled more than 250 children. When the children were 4 weeks old, their body dimensions and lung function were measured. At the same time, their parents completed questionnaires about such factors as smoking during pregnancy.
When the children were 5, the researchers used ultrasound to measure the thickness and flexibility of their carotid arteries, large blood vessels in the neck that supply blood to the brain. They also collected updated smoking information from their parents.
The walls of the carotid arteries in 5-year-olds whose mothers had smoked throughout pregnancy were about 19 microns thicker -- about one to two times the thickness of a piece of cassette tape -- and 15% stiffer than those whose mothers had not smoked.
If both parents smoked while they were in the womb, the children’s carotid arteries were nearly 28 microns thicker and 21% stiffer than those of children whose parents didn’t smoke during pregnancy. These changes may indicate damage to blood vessels that may affect their function, the study authors suggest.
- Dec 29 Thu 2011 04:49
- Dec 28 Wed 2011 04:47
- Dec 27 Tue 2011 11:40
- Dec 26 Mon 2011 05:21
與懷孕期間未使用吸入型腎上腺糖皮質素者之子代相比，在懷孕期間使用吸入型腎上腺糖皮質素之丹麥婦女的子代中，孩童時期的內分泌和代謝異常風險顯著增加(風險比1.84；95% 信心區間1.13 - 2.99)，但其他類別疾病則無；疾病分類是根據國際疾病分類第10版。
- Dec 25 Sun 2011 09:38
- Dec 23 Fri 2011 07:11
Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A. ADVATE is the only antihemophilic factor approved in the United States for prophylactic use in both adults and children.
- Dec 22 Thu 2011 07:30
- Dec 21 Wed 2011 07:28
- Dec 20 Tue 2011 07:19
FDA核准 Jakafi 治療骨髓纖維化的藥物
The U.S. Food and Drug Administration today approved Jakafi (ruxolitinib), the first drug approved to specifically treat patients with the bone marrow disease myelofibrosis.
- Dec 18 Sun 2011 06:57
- Dec 17 Sat 2011 06:49
- Dec 16 Fri 2011 06:35
Bazedoxifene (Conbriza®, Viviant®) is the first third-generation selective estrogen receptor modulator (SERM) and it is approved for the treatment of postmenopausal osteoporosis in the EU and Japan. Bazedoxifene contains an indole-based core binding domain that binds with high affinity to estrogen receptors and exhibits favourable effects on bone and lipid profiles, with no clinically relevant endometrial or breast stimulation. Oral bazedoxifene once daily reduced the incidence of new vertebral fractures in patients with postmenopausal osteoporosis in a large, well designed trial of 3 years' duration; both bazedoxifene and raloxifene were significantly more effective than placebo. Neither bazedoxifene nor raloxifene reduced the incidence of nonvertebral fractures in the overall study population; however, bazedoxifene, but not raloxifene, reduced the rate of nonvertebral fractures in high-risk patients. Moreover, data from patients who continued to receive the drug during a 2-year extension phase of this trial indicate that bazedoxifene continues to provide protection against new vertebral fractures for up to 5 years. Bazedoxifene also increases bone mineral density and reduces the levels of bone turnover markers. Bazedoxifene was generally well tolerated and did not detrimentally affect the reproductive tract or breast tissue in clinical trials, thereby demonstrating a favourable risk-benefit profile. A pharmacoeconomic analysis conducted from an EU perspective predicted bazedoxifene to be cost effective in some EU countries. Therefore, bazedoxifene presents another useful option for the treatment of postmenopausal osteoporosis, especially in those at high risk for osteoporotic fracture.
- Dec 15 Thu 2011 07:19
By Dr Ananya Mandal, MD
The U.S. Centers for Disease Control and Prevention (CDC) has released new guidelines on treating so-called “latent” tuberculosis (TB) infection in the United States. They suggest the course of the therapy from about 9 months could be shortened to 3 months.
- Dec 14 Wed 2011 07:14
- Dec 13 Tue 2011 12:08
- Dec 12 Mon 2011 10:03
Rheumatoid arthritis is a common autoimmune disease that is associated with progressive disability, systemic complications, early death, and socioeconomic costs.1 The cause of rheumatoid arthritis is unknown, and the prognosis is guarded. However, advances in understanding the pathogenesis of the disease have fostered the development of new therapeutics, with improved outcomes. The current treatment strategy, which reflects this progress, is to initiate aggressive therapy soon after diagnosis and to escalate the therapy, guided by an assessment of disease activity, in pursuit of clinical remission.